

SAFETY DATA SHEET



Revision date: 10-Feb-2015

Version: 2.1

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Methylprednisolone Tablets (4 mg)

Trade Name: MEDRONE V, MEDROL, MODERIN

Synonyms: MODERIN TABLETS 4 mg

Chemical Family: Corticosteroid hormone

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product

Restrictions on Use: Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:
Animal Health Division (office hours): +44 (0)1737 331333

2. HAZARDS IDENTIFICATION

Appearance: White tablets

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A

Specific target organ systemic toxicity (repeated exposure): Category 2

EU Classification:

EU Indication of danger: Harmful

Toxic to reproduction: Category 1

EU Symbol: T

EU Risk Phrases:

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

R61 - May cause harm to the unborn child.

Label Elements

Signal Word: Danger

Hazard Statements: H360 - May damage fertility or the unborn child
H373 - May cause damage to organs through prolonged or repeated exposure (blood and blood forming organs , reproductive system , adrenal gland)

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 2 of 10
Version: 2.1

Precautionary Statements:

- P201 - Obtain special instructions before use
- P202 - Do not handle until all safety precautions have been read and understood
- P280 - Wear protective gloves/protective clothing/eye protection/face protection
- P260 - Do not breathe dust/fume/gas/mist/vapors/spray
- P308 + P313 - IF exposed or concerned: Get medical attention/advice
- P314 - Get medical attention/advice if you feel unwell
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards

Short Term:

Long Term:

May be absorbed through the skin and cause systemic effects.
Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs. May cause allergic reactions in susceptible individuals following repeated contact with this material. Repeat-dose studies in animals have shown a potential to cause adverse effects on the hematological and reproductive systems. may have the potential to produce effects on the developing fetus.

Known Clinical Effects:

Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations.

Australian Hazard Classification (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Methylprednisolone	83-43-2	201-476-4	Xn;R48/22 Repr.Cat.1;R61	Repr. 1A (H360) STOT RE 2 (H373)	4 mg
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	<10
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	<5
Calcium stearate	1592-23-0	216-472-8	Not Listed	Not Listed	<1
Mineral oil	8012-95-1	232-384-2	Not Listed	Not Listed	<1

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sorbic acid	110-44-1	203-768-7	Not Listed	Not Listed	*
Lactose	63-42-3	200-559-2	Not Listed	Not Listed	*

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 3 of 10
Version: 2.1

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 4 of 10
Version: 2.1

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

When handling, use proper personal protective equipment as specified in Section 8. Avoid contact with eyes, skin and clothing. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Prevent environmental releases.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Methylprednisolone

Zoetis OEL TWA 8-hr 4 µg/m³, Skin

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 5 of 10
Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Calcium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Mineral oil

ACGIH Threshold Limit Value (TWA)	5 mg/m ³
Australia TWA	5 mg/m ³
Belgium OEL - TWA	5 mg/m ³
Bulgaria OEL - TWA	5.0 mg/m ³
Czech Republic OEL - TWA	5 mg/m ³
Denmark OEL - TWA	1 mg/m ³
Finland OEL - TWA	5 mg/m ³
Greece OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	1 mg/m ³
Netherlands OEL - TWA	5 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³
OSHA - Final PELs - TWAs:	5 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 mg/m ³
Romania OEL - TWA	5 mg/m ³
Slovakia OEL - TWA	5 ppm
	1 mg/m ³
	5 mg/m ³
Spain OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	1 mg/m ³

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Wear impervious gloves if skin contact is possible.
Eyes:	Safety glasses or goggles
Skin:	Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	White
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	Insoluble		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 6 of 10
Version: 2.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

No data available

Methylprednisolone

Predicted 7.4 Log D 1.99

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: Thermal decomposition products may include carbon monoxide, carbon dioxide and other toxic vapors.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been investigated. The information in this section describes the potential hazards of the individual ingredients and the formulation.
Routes of exposure: eye contact , skin contact

Acute Toxicity: (Species, Route, End Point, Dose)

Sorbic acid

Rat Oral LD50 7360 mg/kg

Mouse Oral LD50 3200mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Methylprednisolone

Rat Oral LD 50 > 2000 mg/kg

Mouse Oral LD 50 450mg/kg

Rat Intraperitoneal LD 50 1000mg/kg

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 7 of 10
Version: 2.1

11. TOXICOLOGICAL INFORMATION

Mouse Intraperitoneal LD 50 1409mg/kg

Rat Subcutaneous LD 50 >3000mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Mineral oil

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Mild

Methylprednisolone

Skin Irritation Rabbit No effect

Eye Irritation Rabbit No effect

Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Methylprednisolone

42 Day(s) Dog Oral 167 µg/kg/day LOAEL Adrenal gland

6 Week(s) Rat Subcutaneous 500 µg/kg/day LOAEL None identified

14 Week(s) Rat Subcutaneous 0.4 µg/kg/day NOAEL Blood forming organs, Adrenal gland

52 Week(s) Rat Subcutaneous 4 µg/kg/day NOAEL Blood forming organs Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Methylprednisolone

Reproductive & Fertility Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity

Reproductive & Fertility Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity

Embryo / Fetal Development Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic

Embryo / Fetal Development Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic

Embryo / Fetal Development Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Methylprednisolone

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Unscheduled DNA Synthesis Rat Hepatocyte Negative

Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative

Direct DNA Interaction Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 8 of 10
Version: 2.1

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties of the formulation have not been investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential: Methylprednisolone Predicted 7.4 Log D 1.99	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Should not be released into the environment. Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
---------------------------------	--

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A

This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all of the information required by the CPR.



SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 9 of 10
Version: 2.1

15. REGULATORY INFORMATION

Methylprednisolone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	201-476-4

Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

Calcium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	216-472-8

Mineral oil

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-384-2

Sorbic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-768-7

Lactose

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets (4 mg)
Revision date: 10-Feb-2015

Page 10 of 10
Version: 2.1

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-559-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1A; H360 - May damage fertility or the unborn child
Specific target organ toxicity, repeated exposure-Cat.1; H373 - May cause damage to organs through prolonged or repeated exposure

Toxic to reproduction: Category 1
Xn - Harmful

R61 - May cause harm to the unborn child.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information.

Prepared by: Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet